Analysing both analytes found twice as many mutations, which could be used as potential biomarkers to guide treatment. Angle is keen to align the Parsortix system with Illumina’s next generation ...

enabling analysis of large gene panels and cancer specific mutations. Illumina is the world’s largest provider of NGS systems and assays and has built an installed base of more than 23,000 sequencing ...

enabling analysis of large gene panels and cancer specific mutations. Illumina is the world's largest provider of NGS systems and assays and has built an installed base of more than 23,000 sequencing ...

There were also mutations identified in ctDNA alone ... to undertake multiomics by enabling RNA and protein sequencing on Illumina platforms which is not possible with ctDNA.

There were also mutations identified in ctDNA alone ... to undertake multiomics by enabling RNA and protein sequencing on Illumina platforms which is not possible with ctDNA.

Angle PLC on Wednesday released successful results from its new dual circulating tumour DNA and circulating tumour cell DNA workflow, using Illumina Inc's sequencing technology for the first time. The ...

Illumina, Inc. introduced PrimateAI-3D, an advanced artificial intelligence (AI) software designed to precisely predict disease-causing genetic mutations, further increasing demand for genomic ...